Different pyruvate kinase isoforms are expressed in a tissuespecific manner, with pyruvate kinase M2 (PKM2) suggested to be the predominant isoform in proliferating cells and cancer cells. Because of differential regulation of enzymatic activities, PKM2, but not PKM1, has been thought to favor cell proliferation. However, the role of PKM2 in tumorigenesis has been recently challenged. Here we report that increased glucose catabolism through glycolysis and increased pyruvate kinase activity in c-MYC-driven liver tumors are associated with increased expression of both PKM1 and PKM2 isoforms and decreased expression of the liver-specific isoform of pyruvate kinase, PKL. Depletion of PKM2 at the time of c-MYC overexpression in murine livers did not affect c-MYC-induced tumorigenesis and resulted in liver tumor formation with decreased pyruvate kinase activity and decreased catabolism of glucose into alanine and the Krebs cycle. An increased PKM1/ PKM2 ratio by ectopic PKM1 expression further decreased glucose flux into serine biosynthesis and increased flux into lactate and the Krebs cycle, resulting in reduced total levels of serine. However, these changes also did not affect c-MYCinduced liver tumor development. These results suggest that increased expression of PKM2 is not required to support c-MYC-induced tumorigenesis in the liver and that various PKM1/PKM2 ratios and pyruvate kinase activities can sustain glucose catabolism required for this process.
Introduction
Aberrant cellular metabolism is one of the hallmarks of cancer (1) . Increased glucose transport and metabolism are among the most prominent metabolic abnormalities observed in multiple tumors and cancer models (2, 3) . Metabolic changes, in part triggered by expression changes of genes encoding metabolic enzymes, are thought to ensure survival and proliferation of cancer cells by providing enough ATP and macromolecule precursors. Several enzymes or enzyme isoforms overexpressed in different tumor types have been shown to be required for tumorigenesis or are even able to initiate tumorigenesis (2, 3) .
Pyruvate kinase catalyzes the final step in glycolysis by transferring the phosphate from phosphoenolpyruvate (PEP) to ADP, thereby generating pyruvate and ATP (4) . Mammalian pyruvate kinases are encoded by two genes (PKLR and PKM), and each can generate two isoforms, respectively (PKL and PKR; PKM1 and PKM2). These isoforms have distinct kinetic properties and tissue distribution. Different tissue promoters drive the expression of PKL or PKR isoforms from the PKLR locus, thus generating two tissue-specific mRNA species (5, 6) . PKR is exclusively expressed in erythrocytes, whereas PKL is primarily expressed in liver, kidney, and small intestine (5, 6) . PKM1 and PKM2 are alternative splicing products of the PKM gene and expressed in various tissues (4) . PKM1 is found in some differentiated adult tissues, such as heart, muscle, and brain (7, 8) . PKM2 is widely expressed and a predominant isoform in many adult cell types, including kidney tubular cells, intestinal epithelial cells, and lung epithelial cells (8, 9) ; and it is also considered to be the dominant isoform in proliferating cells, including embryonic and adult stem cells as well as cancer cells (7) . In contrast to PKM1, which has constitutively high pyruvate kinase activity, PKM2 was shown to exist in either a less active or a more active form (10) (11) (12) . The transition between these two PKM2 forms can be regulated allosterically by the upstream intermediate of glycolysis, fructose-1,6-bisphosphate (FBP), and by serine, as well as by interaction with tyrosine phosphorylated proteins and by oxidation (11, (13) (14) (15) (16) . The differential characteristics of the two PKM isoforms have been shown to have a direct impact on glycolysis and cell proliferation. Christofk and colleagues showed that in cancer cells whose endogenous PKM2 expression was suppressed by shRNA, the ectopic expression of PKM2 resulted in higher ability to generate xenograft tumors than ectopic expression of PKM1 (15) . Moreover, ectopic expression of PKM1 without silencing PKM2 expression resulted in increased PK activity and decreased ability to form xenograft tumors (12) . Consistent with this, PKM2 activators, which increase its pyruvate kinase activity by promoting the formation of the tetrameric form, have been shown to reduce the ability of cells to form xenograft tumors (12, 17) . Finally, knockout of PKM2 in mouse embryonic fibroblasts resulted in compensatory expression of PKM1, diversion of glucose flux from nucleotide biosynthesis into lactate and the Krebs cycle, and, eventually, proliferation arrest (18) . All these observations led to the hypothesis that expression of PKM2 rather than PKM1 would provide proliferating cells with a differential control over the glycolytic flux. Decreased PKM2 activity as the result of allosteric regulation could permit the accumulation of intermediates upstream of PEP, increasing the flux into biosynthetic and antioxidative pathways whereas activation of PKM2 or high pyruvate kinase activity as the result of PKM1 expression can inhibit tumorigenesis (19) . A nonenzymatic protumorigenic role of PKM2 has also been suggested (18, (20) (21) (22) . However, recent precise absolute quantifications of the PKM1 and PKM2 protein content challenged the exclusive association of proliferative state with PKM2 expression. Bluemlein and colleagues demonstrated the presence of both PKM1 and PKM2 in most of the tumor and normal adjacent tissue samples analyzed, including kidney, bladder, colon, lung, and thyroid (9) . Although expression of both PKM1 and PKM2 were increased in tumors in comparison with their normal tissue counterparts, PKM2 was a predominant form in both normal and tumor tissues in most of the cases (9) . Dayton and colleagues also demonstrated expression of PKM2 in kidney tubular cells, intestinal and lung epithelial cell, and pancreatic islet cells (8) . Strikingly, tissue-specific knockout of PKM2 did not affect the formation of mammary gland tumors in BRCA1 À/À ; p53 þ/À mice, which have high expression of PKM2 and low expression of PKM1 (23) . The resulting PKM2-null tumors had heterogenous PKM1 expression, which led the authors to conclude that PKM1 was either present in non-proliferating or was low in proliferating tumor cells. The authors suggested that PKM1 expression was kept low to maintain the low pyruvate kinase activity supporting cell proliferation (23) . In another study, inducible knockdown of either PKM2 alone or both PKM1 and PKM2 in cancer cells with predominant expression of PKM2 inhibited proliferation of cells in culture, but neither affected xenograft tumor progression (24) . The proposed glycolysis-independent role of PKM2 in tumorigenesis has recently also been challenged (25) . Finally, germline loss of PKM2 can be compensated by PKM1 expression in embryonic tissues and PKM2-expressing adult tissues and does not affect normal development (8) . Altogether, these results suggest that increased PKM2 expression may not be essential for cell proliferation and tumorigenesis in vivo and the precise role of different pyruvate kinase isoforms in supporting these processes in different in vivo settings remains to be elucidated. Amplification of the c-Myc protooncogene has been found in 40% to 60% of early hepatocellular carcinoma samples (26) , where it acts as a master regulator of cellular proliferation, apoptosis, and metabolism (27) . Our previous studies demonstrated that liver tumors induced by liver-specific overexpression of c-MYC have increased catabolism of glucose through glycolysis in comparison with normal liver tissue (28) . Using the same mouse model, it was shown that c-MYC-induced liver tumors exhibit increased expression of the Pkm gene (29) . Here we demonstrate that c-MYC induced liver tumors have significantly increased expression of both PKM1 and PKM2, compared with normal liver tissue. Interestingly, significantly decreasing PKM2 expression in tumors results in the diminished pyruvate kinase activity to the level comparable with normal liver. However, this decrease does not reduce glucose flux proportionally and does not affect tumor formation and progression. Moreover, ectopic PKM1 overexpression in the context of PKM2 inhibition, which diverts glucose flux from serine biosynthesis into lactate and the Krebs cycle, does not affect tumorigenesis either. Our results suggest that increased PKM2 expression is not required for c-MYC-induced tumorigenesis in the liver and that this process can be sustained by various pyruvate kinase activities and PKM1/PKM2 ratios.
Materials and Methods

Constructs and reagents
The constructs for mouse injection, including pT3-EF1a-c-MYC and pCMV/SB (which encodes for sleeping beauty transposase or SB), were previously described (30) . Mcl1 and PKM1 plasmids were obtained from Addgene [Addgene catalog no. 25714 for Mcl1 (with HA tag) and 34607 for PKM1 (with V5 tag)], and cloned into pT3-EF1a vector via the Gateway cloning strategy (Invitrogen). miR30-based shRNA targeting for PKM1/2 3 0 UTR and a previously published shRNA against Renilla luciferase (31) were cloned into pT3-EF1a-c-MYC via the Gateway PCR cloning strategy to generate pT3-EF1a-c-Myc-shPKM and pT3-EF1a-cMyc-shLuc plasmids, respectively ( Supplementary Fig. S1 ). Plasmids were purified using the Endotoxin-Free Maxiprep Kit (Sigma-Aldrich).
13
C6-glucose was purchased from Cambridge Isotope Laboratories, Inc.
Hydrodynamic injection and mouse monitoring
Wild-type FVB/N mice were obtained from Jackson Laboratory. Hydrodynamic injection was performed as described (32) . In brief, 10 mg of pT3-EF1a-c-MYC-shPKM or pT3-EF1a-c-MYCshLuc with 5 mg of pT3-EF1a-Mcl1 along with sleeping beauty transposase in a ratio of 25:1 were diluted in 2 mL of saline (0.9% NaCl), filtered through 0.22-mm filter, and injected into the lateral tail vein of 6-to 8-week-old FVB/N mice in 5 to 7 seconds. Mice were housed, fed, and monitored in accordance with protocols approved by the Committee for Animal Research at the University of California, San Francisco.
Western blotting
Mouse liver tissues were processed as previously reported (33) . Protein lysates were fractionated by SDS-PAGE and transferred to nitrocellulose membranes. Membranes were blocked in 5% nonfat dry milk for 1 hour and incubated with primary antibodies against PKM1 (1:1,000; Cell Signaling Technology), PKM2 (1:1,000; Cell Signaling Technology), PKM1/2 (1:1,000; Cell Signaling Technology), PKLR (1:1,000, Abcam), c-MYC (1:1,000; Cell Signaling Technology), PCNA (1:1,000; Cell Signaling Technology), PLK1 (1:1,000; Cell Signaling Technology), HK1 (1:1,000; Cell Signaling Technology), HK2 (1:1,000; Cell Signaling Technology), HK4 (1:1,000; Santa Cruz Biotechnology, Inc.), PFKM (1:1,000; GeneTex, Inc.), PFKL (1:1,000; Proteintech Group, Inc.), PFKP (1:1,000; Gene Tex, Inc.), GLS1 (1:1,000; Abcam), b-actin (1:4,000; Sigma-Aldrich), overnight, and then incubated with secondary antibodies for 1 hour. Bands were visualized using an enhanced chemiluminescence system (ECL, Amersham), according to the manufacturer's instructions. b-Actin and/or GAPDH were used as loading control.
Immunohistochemical staining
Liver specimens were fixed in 4% paraformaldehyde and embedded in paraffin. IHC was performed as previously described (34) . The primary antibodies include: anti-c-MYC (1:200; Abcam), anti-PKM2 (1:800; Cell Signaling Technology), anti-V5 (1:5,000; Invitrogen), anti-Ki67 (1:150; Thermo Fisher), and anti-PKLR (1:500; Abcam).
Pyruvate kinase assay
PK activity of liver and tumor tissues was measured using the Pyruvate Kinase Activity Assay Kit (Sigma-Aldrich), according to the manufacturer's protocol. Protein concentration was quantified using BAC Protein Assay Kit (Thermo Scientific). Pyruvate Kinase activity for each sample was normalized to the final protein concentration.
Assessment of proliferation
Proliferation index was calculated by counting malignant hepatocytes stained positive for Ki67 (Bethyl Laboratories) in at least 3,000 cells per each tumor investigated.
C-glucose experiment
Evaluation of glucose catabolism using 13 C-glucose bolus injection has been described previously (28, 35) . Briefly, 20 mg of 13 C6-glucose dissolved in 100 mL saline was injected into the tail vein of each mouse. Fifteen minutes after the injection, mice were euthanized; the plasma and liver tissues were collected immediately and snap frozen in liquid nitrogen for subsequent metabolic analysis.
Stable isotope labeling and metabolite extraction from tissues
Freeze-clamped tissues were ground in liquid nitrogen with mortar and pestle and subsequently lyophilized on a FreeZone Freeze Dry System (Labconco). Metabolite extraction in mice tissues and derivatization of polar samples were performed essentially as previously described (36) . Briefly, 5 mg of dry weight per sample were extracted with 1.8 mL of chloroform:methanol (2:1, v/v) containing internal standards [10 nmol scylloinositol, 10 nmol L-Norleucine, and 160 nmols of 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS)] for 1 hour at 4 C with intermittent sonication. After centrifugation (18,000 g for 10 minutes at 4 C), the supernatant (SN1) was vacuum dried in rotational-vacuumconcentrator RVC 2-33 CD (Christ). The pellet was re-extracted with methanol:water (2:1, v/v) as described above. After centrifugation, supernatant (SN2) was vacuum dried in the SN1 tube. Phase partitioning (chloroform:methanol:water, 1:3:3, v/v) was used to separate polar and apolar metabolites. Fractions were vacuum dried as described above and the fraction containing the polar metabolites fraction were washed twice with methanol, derivatized by methoximation (Sigma, 20 mL, 20 mg/mL in pyridine) and trimethylsilylation [20 mL of N,O-bis(trimethylsilyl)trifluoroacetamide reagent (BSTFA) containing 1% trimethylchlorosilane (TMCS), Supelco], and analyzed on an Agilent 7890A-5975C GC-MS system (36, 37) . Splitless injection (injection temperature 270 C) onto a 30 m þ 10 m Â 0.25 mm DB-5MSþDG column (Agilent J&W) was used, using helium as the carrier gas, in electron ionization (EI) mode. The initial oven temperature was 70 C (2 minutes), followed by temperature gradients to 295 C at 12.5 C/minute and then to 320 C at 25 C/minute (held for 3 minutes). Metabolite quantification and isotopomer distributions were corrected for the occurrence of natural isotopes in both the metabolite and the derivatization reagent. Data analysis and peak quantifications were performed using MassHunter Quantitative Analysis software (B.06.00 SP01, Agilent Technologies). The level of labeling of individual metabolites was corrected for natural abundance of isotopes in both the metabolite and the derivatization reagent (30) . Abundance was calculated by comparison to responses of known amounts of authentic standards.
NMR spectra were acquired at 25 C with a Bruker Avance III HD instrument with a nominal 1H frequency of 800 MHz using 3-mm tubes in a 5 mm CPTCI cryoprobe. For 1H 1D profiling spectra, the Bruker pulse program noesygppr1d was used with a 1-second presaturation pulse (50 Hz bandwidth) centred on the water resonance, 0.1 milliseconds mixing time, and 4 seconds acquisition time at 25 C. Typically 128 transients were acquired.
Statistical analysis
Student t and one-way ANOVA with Tukey post hoc tests were used to evaluate statistical significance as indicated in figure legends; and Kaplan-Meier method was for survival analysis. Value of P < 0.05 were considered significant. Data are expressed as mean AE SD.
Results
Increased glycolysis in c-Myc-induced liver tumors is associated with increased PKM1 and PKM2 expression
In our previous study, we demonstrated that liver tumors from CEBPb-tTA-TRE-c-MYC transgenic mice exhibit increased levels of glycolysis compared to normal liver tissue (28) . To generate c-MYC driven tumors in adult murine livers, we delivered a Sleeping-Beauty Transposon vector encoding the c-MYC oncogene into mice by hydrodynamic injection (30) . We found that enforced c-MYC expression consistently led to tumor formation in FVB/N mice obtained from Jackson Laboratory, whereas c-MYC injection failed to induce liver tumor formation or induced liver tumors with significant delay and decreased penetrance in many other strains tested. This inconsistency could be explained by previous observations that overexpression of c-MYC induces apoptosis that can lead to elimination of c-MYC-transformed cells in vivo (38) . The tissue environment may be more or less supportive of the survival of c-MYC-transformed hepatocytes in different genetic backgrounds (39) , which would result in tumor formation upon c-MYC overexpression in some mouse strains but not others. To generate consistently highly penetrant liver tumors in all mouse strains, we co-injected plasmids expressing c-MYC and MCL1, an antiapoptotic member of BCL2 protein family and found that this combination (c-MYC/MCL1) induces liver tumor formation in 5 to 8 weeks in all mouse strains tested, including C57BL/6, FVB/N, and Balb/C mice ( Supplementary Fig. S2 ).
In the further experiments, pT3-EF1a-c-MYC vector also carried a small hairpin against Renilla luciferase (shLuc), which did not affect c-MYC/MCL1 tumor latency. c-MYC-shLuc/MCL1 liver tumors showed equivalent histopathologic features to those of CEBPb-tTA-TRE-c-MYC liver tumors and c-MYC/MCL1. All tumor cells expressed ectopic human c-MYC oncogene and tumors were highly proliferative (Fig. 1A) . Similar to CEBPb-tTA-TRE-c-MYC tumors, c-MYC-shLuc/MCL1 tumors had increased glucose catabolism (28, 40) , as suggested by increased contribution of glucose to the pools of lactate, glycolytic intermediates, PEP and 3-phosphoglycerate (3-PG), and the Krebs cycle intermediates (Fig.  1B and C) . Importantly, increased glucose catabolism in c-MYC/ MCL1 and c-MYC-shLuc/MCL1 tumors was associated with increased expression of both PKM1 and PKM2 (Figs. 1D  and 2A ). c-MYC/MCL1 and c-MYC-shLuc/MCL1 tumors also had liver-specific isoform of pyruvate kinase, PKL, expressed as detected with the antibodies against the product of PKLR gene. However, its expression was very low (Fig. 1D and 2A ) and was not detected in all of the tumor cells (Fig. 1E) . These changes in the expression of pyruvate kinase isoforms in c-MYC-shLuc/MCL1 tumors were associated with increased pyruvate kinase activity in comparison with the normal liver (Fig. 2B) .
Decreased PKM2 expression results in decreased pyruvate kinase activity but does not affect c-MYC-induced liver tumorigenesis Given the contradictory results about the role of PKM isoforms in tumorigenesis, we thought to evaluate if differential expression of the isoforms and pyruvate kinase activity would have any effect on c-MYC-driven liver tumorigenesis. Two miR30-based shRNAs against mouse PKM 3 0 -UTR, which are common for both PKM1 and PKM2 (shPKM.1 and shPKM.2, Supplementary Fig. S1 ), were first tested in vitro in a cell line derived from CEBPb-tTA-TREc-MYC tumors (Supplementary Fig. S3; ref. 41 ). Both shPKMs significantly decreased the expression of PKM1 and PKM2 compared to a control shRNA (shLuc), but did not affect cell proliferation in culture (Supplementary Fig. S3 ).
To investigate whether silencing of PKM1 and PKM2 expression affects c-MYC-induced tumorigenesis in the liver in vivo, we cloned shPKM and shLuc into pT3-EF1a-c-MYC plasmid (Supplementary Fig. S4 ). The plasmids were hydrodynamically injected into mice together with the vector encoding MCL1 Ã , P < 0.05, ÃÃ , P < 0.01, ÃÃÃ , P < 0.001. D, PKM1/2 and PKLR protein levels measured in whole-tissue lysates from normal and tumor samples by immunoblotting using b-actin and GAPDH as a loading control. E, Expression of PKM2 and PKLR examined by IHC in normal livers and c-MYC/MCL1 liver tumors. Scale bars, 100 mm.
(c-MYC-shPKM/MCL1 and c-MYC-shLuc/MCL1, respectively; Supplementary Fig. S4 ). In contrast to its effect in vitro, shPKM strongly decreased PKM2 expression while having only minor effect on PKM1 expression ( Fig. 2A; Supplementary Figs. S5 and S6). Pyruvate kinase activity was decreased in c-MYC-shPKM/ MCL1 tumors to the level observed in the normal liver (Fig. 2B) , suggesting that increased PKM2 expression is mostly responsible for the increased pyruvate kinase activity in c-MYC liver tumors. c-MYC-shPKM/MCL1 tumors had PKL levels comparable to those in c-MYC-shLuc/MCL1 tumors ( Fig. 2A; Supplementary Fig. S5 ), which together with PKM1 may be supporting the pyruvate kinase activity observed. Expression of other key enzymes involved in glycolysis including hexokinases (HK1, HK2, and HK4) and phosphofructokinases (PFKP, PFKM, and PFKL) as well as the first enzyme of glutamine catabolism, GLS1 also did not change in c-MYC-shPKM/MCL1 tumors in comparison with c-MYC-shLuc/ MCL1 tumors ( Supplementary Fig. S6 ). Overall, shPKM specifically decreased PKM2 expression, leading to lower pyruvate kinase activity, but it did not affect the expression of other genes in either glucose or glutamine catabolism.
In both groups of mice, tumors developed between 5 and 8 weeks postinjection. There was no difference in survival rate, liver weight, and liver/body ratio between c-Myc-shLuc/Mcl1 and c-Myc-shPKM/Mcl1 mice ( Fig. 2C; Supplementary Figs. S7 ). Histologically, both c-MYC-shPKM/MCL1 and c-MYC-shLuc/MCL1 tumors were composed of small tumor cells with large nuclei, consistent with the features of c-MYC-induced liver tumors as described by others (Supplementary Fig. S7; ref. 42 ). Furthermore, we did not observe significant differences in proliferation in c-MYC-shPKM/MCL1 and c-MYC-shLuc/MCL1 tumors with the proliferation index 65.7 AE 11.1 in c-MYC-shPKM/MCL1 and 68.8 AE 9.2 in c-MYC-shLuc/MCL1 (P > 0.05; n ¼ 9 for each group). Consistent with this, no difference was observed in the expression of proliferation associated proteins, including cyclin D1, PCNA, and Polo-like kinase (PLK1) between c-MYC-shLuc/MCL1 and c-MYC-shPKM/MCL1 tumors ( Fig. 2A) .
Silencing of PKM2 expression results in altered glucose catabolism.
To evaluate how decreased expression of PKM isoforms and resultant decrease in pyruvate kinase activity affect glucose catabolism, we injected tumor-bearing animals with 13 C6-glucose and evaluated the total levels and the levels of 13 C-labeled metabolites by GC-MS and NMR. Consistent with decreased pyruvate kinase activity c-MYC-shPKM/MCL1 tumors had significantly higher levels of total and 13 C-labeled PEP, 3PG, and serine than c-MYC-shLuc/MCL1 tumors ( Fig. 3A and B) . Increased levels of glycolytic intermediates upstream of pyruvate kinase in c-MYCshPKM/MCL1 tumors were associated with decreased levels of 13 C-labeled alanine and the Krebs cycle intermediates (Fig. 3A) , indicating that decreased pyruvate kinase activity in c-MYCshPKM/MCL1 tumors resulted in decreased glucose catabolism below the pyruvate kinase step. These changes were associated with significant decrease in total fumarate levels, but not those of alanine or malate (Fig. 3B) . Interestingly, the levels of total and 13 C-lactate were not affected in c-MYC-shPKM/MCL1 tumors in comparison with c-MYC-shLuc/MCL1 tumors ( Fig. 3A and B ). These results demonstrate that increased pyruvate kinase activity in c-MYC-induced liver tumors supports increased glycolytic flux. However, pyruvate kinase activity at the levels observed in the normal liver tissue can still support the glycolytic flux higher than the one observed in the normal liver and presumably created by glycolytic steps upstream of pyruvate kinase. Significantly decreasing PKM2 expression in tumor cells ( Fig. 2A) does not affect the initiation of proliferation and survival of c-MYC-transformed liver cells.
Increasing PKM1/PKM2 ratio does not affect c-Myc-induced liver tumorgenesis.
Increasing pyruvate kinase activity by ectopic overexpression of PKM1 or using PKM2 activators was previously shown to impair the ability of cancer cells to form xenograft tumors (12, 43) . Moreover, mammary gland tumor-derived cells with deleted PKM2 and ectopic overexpression of PKM1 were not able to develop tumors, whereas cells with just deleted PKM2 were (23) . These works suggested that increasing PKM1 levels or constitutively activating pyruvate kinase can be detrimental for cancer cell proliferation in vivo by, for example, diverting the glucose flux from the synthesis of anabolic precursors. In c-MYCshPKM/MCL1 tumors, the decrease in PKM2 levels was more significant than the decrease in PKM1 levels in comparison with c-MYC-shLuc/MCL1 tumors, suggesting that PKM1/PKM2 ratio in c-MYC-shPKM/MCL1 was higher than in c-MYC-shLuc/MCL1 tumors. However, to ensure that PKM1/PKM2 ratio is significantly increased and to recapitulate the conditions used in other systems, we ectopically overexpressed PKM1 cDNA with C-terminal V5 tag together with decreasing PKM2 expression by expressing shPKM (Supplementary Fig. S8 ). In brief, we injected mice with pT3 vector expressing c-MYC-shPKM, pT3 vector expressing MCL1, and with either empty pT3 vector (c-MYC-shPKM/MCL1/empty) or pT3 expressing PKM1 (c-MYC-shPKM/MCL1/PKM1). It is important to note that the co-injected PKM1 plasmid did not contain 3 0 -UTR and therefore could not be targeted by shPKM. PKM1 was confirmed to be uniformly expressed in c-MYCshPKM/MCL1/PKM1 tumor cell via anti-V5 immunostaining (Supplementary Fig. S8 ).
c-MYC-shPKM/MCL1/PKM1 tumors demonstrated significantly higher PKM1/PKM2 ratio than c-MYC-shLuc/MCL1 and c-MYC-shPKM/MCL1/empty tumors (Fig. 4A) . Pyruvate kinase activity measured in tissue lysates from c-MYC-shPKM/MCL1/ PKM1 tumors was higher than in c-MYC-shPKM/MCL1/empty tumors and comparable with c-MYC-shLuc/MCL1 tumors (Fig.  4B) . Evaluating glucose catabolism in c-MYC-shPKM/MCL1/ PKM1 tumors demonstrated significant decrease in the levels of 13C-labeled PEP, 3PG, serine but increased levels of 13C-labeled lactate and the Krebs cycle intermediates, malate and fumarate, in comparison with c-MYC-shPKM/MCL1/empty tumors (Fig. 5A) . As demonstrated by total carbon enrichment from PKM1/2 knockdown reduces PK flux in vivo. Livers and tumors from mice injected with 13 C-glucose boluses were analyzed by GC-MS. A, The fate of 13 C from 13 C 6 -glucose through glycolysis, into the Krebs cycle, and amino acid synthesis is depicted; the levels of 13 Clabeled metabolites are expressed as nmols of 13 C molecules (sum of all isotopomers except Mþ0) per mg of dry tissue. B, Total concentration of metabolites is presented. In both panels, data are presented as mean AE SD; #, P < 0.05; ##, P < 0.01; ###, P < 0.001 relative to normal liver and was higher even in comparison with the initial c-MYC-shLuc/ MCL1 tumors (Fig. 5B) . The redistribution of the glucose-derived carbons in c-MYC-shPKM/MCL1/PKM1 tumors resulted in the decreased total serine levels (Fig. 5C ), which were lower than in c-MYC-shPKM/MCL1/empty (Fig. 5C ) and the initial c-MYCshLuc/MCL1 tumors (Fig. 3B) . Regardless of this diverted flux, however, the latency and burden of c-MYC-shPKM/MCL1/PKM1 tumors was not statistically significantly different from c-MYCshPKM/MCL1 tumors (Fig. 4C) .
Overall, our data demonstrate that presence of a specific pyruvate kinase isoform is not required to support the initiation and progression of MYC-induced tumorigenesis in the liver. Moreover, partial suppression or activation of the pyruvate kinase flux is not sufficient to affect oncogenic transformation or tumor progression.
Discussion
The predominant expression of PKM2 in many embryonic tissues, its increased expression in cancer tissues and preferential expression in multiple cancer cell lines have led to a long-standing belief about its requirement for cell proliferation and tumorigenesis. However, several recent reports using PKM2 knockout demonstrating that PKM2 is dispensable for normal embryonic development and either mammary gland tumorigenesis induced by HER2 or spontaneous liver tumorigenesis (8, 24) have challenged this idea.
Because c-MYC has been demonstrated to increase PKM2/ PKM1 ratio by regulating the expression of HnRNP proteins (44), we tested the expression of PKM isoforms and their role in c-MYC-induced tumorigenesis in the liver. In contrast to the results by David and colleagues, c-MYC-induced transformation resulted in significantly increased expression of both PKM1 and PKM2. However, the fact that decreasing PKM2 expression resulted in decreasing tumor pyruvate kinase activity to the normal liver levels indicated that PKM2 is still mostly responsible for the increase in pyruvate kinase activity observed in c-MYCinduced liver tumors.
Inhibiting the expression preferentially of PKM2 together with ectopically expressing c-MYC in hepatocytes resulted in tumors with decreased pyruvate kinase activity and increased flux of glucose into serine biosynthesis on the expense of its catabolism through the Krebs cycle. However, consistent with the results obtained in PKM2 knockout mouse models (24) , these changes in PKM2 expression and glycolytic flux did not affect either tumor initiation or progression. Pyruvate kinase activity at the level of the normal liver, which is maintained possibly by the expression of PKM1 and PKLR isoforms, was sufficient to support glycolytic flux and flux of glucose through the Krebs cycle required to sustain the level of vital metabolites and metabolic activities. Interestingly, one of the early studies evaluating the expression of PK isoforms in the liver of rats treated with choline/DL-methionine-deficient diet demonstrated that, although being decreased in liver parenchyma, the expression of liver isoform PKL was increased in some proliferating cells during early stages of the treatment and in glycogenolytic cells within dysplastic lesions at later stages (45) . The expression of both PKL and PKM2 was also observed in renal cell carcinomas and their metastasis (46) . Consistent with these earlier observations high expression of PKLR is reported in the liver and renal cancers by The Human Protein Atlas (47) . Intriguingly, germline loss of PKM2 is associated with the formation of HCCs, in which most of the cells were PKM1-negative (8) . These results may additionally suggest the role of PKL in supporting proliferation of tumor cells in the absence of PKM isoforms or the existence of pyruvate kinase-independent mechanism of PEP conversion into pyruvate (48) .
Similar to the previously demonstrated effect of PKM2 activators (49) and selective overexpression of PKM1 (13), ectopically overexpressing PKM1 while decreasing the expression of PKM2 resulted in significantly decreased glucose flux into serine and increased flux into the Krebs cycle intermediates. As a result, tumors with significantly increased PKM1/PKM2 ratio had significantly decreased levels of serine. Interestingly pyruvate kinase activity measured in lysates from c-MYC-shPKM/ MCL1/PKM1 tumors was comparable with the pyruvate kinase activity in the lysates from original tumors confirming the role of allosteric regulation of PKM2 in vivo in regulating glucose flux into the synthesis of biosynthetic precursors. Nevertheless, the significantly decreased levels of serine in c-MYC-shPKM/ MCL/PKM1 tumors are still sufficient to support the pools of serine-derived metabolites and sustain cellular transformation and proliferation of transformed cells in the liver. These results are in contrast to the results demonstrating the deleterious effect of increased PKM1 expression in in vitro systems with ectopic overexpression of PKM1 (12) and in mammary gland tumors and normal fibroblasts, where increased PKM1 expression was the result of PKM2 knockout (18, 24) . The difference in the sensitivity of different systems to increasing pyruvate kinase activity and diverting the glucose flux can be determined by the differential requirements for certain levels of biosynthetic precursors and the ability to utilize the compensatory pathways. On the basis of the results demonstrating the serine auxotrophy in response to PKM2 activators (49), c-MYCshPKM/MCL1/PKM1 tumors can be suggested to be sensitive to depleting serine from the diet.
It is also noteworthy that our current results do not confirm the previously proposed nonenzymatic role of PKM2 in tumorigenesis (20, 50) . In summary, our findings demonstrate that the control of the flux at the pyruvate kinase step is not a requirement for c-MYCdriven liver tumorigenesis, and suggest that different pyruvate kinase isoforms and various pyruvate kinase activities can equally sustain tumor progression. Our findings further denote the difference between previously demonstrated differential role of PKM1 and PKM2 isoforms in vitro and their requirement in tumors developing in their natural environment in vivo.
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